Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,460 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05925491 | Pembrolizumab in Locally Advanced Sinonasal Carcinoma(NeoPeSino) | recruiting | Phase 2 | 28 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02719613 | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | completed | Phase 2 | 67 | Bristol-Myers SquibbINDUSTRY | 13 | Apr 15, 2026 | clinicaltrials |
| NCT04762069 | A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme | active not recruiting | Phase 2 | 252 | CNS Pharmaceuticals, Inc.INDUSTRY | 5 | Apr 15, 2026 | clinicaltrials |
| NCT05635708 | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 400 | BeiGeneINDUSTRY | 15 | Apr 15, 2026 | clinicaltrials |
| NCT06840483 | Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | active not recruiting | Phase 2 | 66 | BicycleTx LimitedINDUSTRY | 7 | Apr 15, 2026 | clinicaltrials |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | recruiting | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 4 | Apr 15, 2026 | clinicaltrials |
| NCT05821556 | Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | recruiting | Phase 2 | 240 | National Cancer Institute, NaplesOTHER | 2 | Apr 14, 2026 | clinicaltrials |
| NCT07213557 | Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy | recruiting | Phase 2 | 84 | National Cancer Institute, NaplesOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05183984 | Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer(NIRVANA-1) | recruiting | Phase 2 | 390 | ARCAGY/ GINECO GROUPOTHER | 6 | Apr 13, 2026 | clinicaltrials |
| NCT05440786 | CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma | active not recruiting | Phase 2 | 46 | Eli Lilly and CompanyINDUSTRY | 7 | Apr 13, 2026 | clinicaltrials |
| NCT07522697 | Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4(MITO END-4) | not yet recruiting | Phase 2 | 48 | National Cancer Institute, NaplesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02625480 | Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma(ZUMA-4) | completed | Phase 1 / Phase 2 | 95 | Kite, A Gilead CompanyINDUSTRY | 11 | Apr 9, 2026 | clinicaltrials |
| NCT03697512 | MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas(MALIBU) | active not recruiting | Phase 2 | 175 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 5 | Apr 8, 2026 | clinicaltrials |
| NCT01968109 | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | completed | Phase 1 / Phase 2 | 1,482 | Bristol-Myers SquibbINDUSTRY | 15 | Apr 6, 2026 | clinicaltrials |
| NCT02087423 | A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer(ATLANTIC) | completed | Phase 2 | 446 | AstraZenecaINDUSTRY | 18 | Apr 6, 2026 | clinicaltrials |
| NCT03459222 | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 229 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 6, 2026 | clinicaltrials |
| NCT04646395 | Study of Acalabrutinib and Tafasitamab in MZL Patients | active not recruiting | Phase 2 | 26 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 3 | Apr 6, 2026 | clinicaltrials |
| NCT06116136 | A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. | active not recruiting | Phase 1 / Phase 2 | 48 | Servier Bio-Innovation LLCINDUSTRY | 15 | Apr 3, 2026 | clinicaltrials |
| NCT03744468 | Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 147 | BeiGeneINDUSTRY | 6 | Apr 2, 2026 | clinicaltrials |
| NCT07290894 | Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01(MITO VULVA-01) | recruiting | Phase 2 | 80 | National Cancer Institute, NaplesOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03793478 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | active not recruiting | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 10 | Apr 1, 2026 | clinicaltrials |
| NCT06305390 | Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer.(RF2021-1237227) | recruiting | Phase 2 | 167 | IRCCS San RaffaeleOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06392009 | Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II | active not recruiting | Phase 1 / Phase 2 | 30 | GRIN Therapeutics, Inc.INDUSTRY | 8 | Apr 1, 2026 | clinicaltrials |
| NCT06341712 | Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma(CabOSTar) | terminated | Phase 2 | 10 | IpsenINDUSTRY | 10 | Mar 31, 2026 | clinicaltrials |
| NCT05586516 | A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 16 | iOncturaINDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT03654105 | Screening and Multiple Intervention on Lung Epidemics(SMILE) | active not recruiting | Phase 2 | 2,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04305548 | Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma(ISG-MCS) | recruiting | Phase 2 | 16 | Italian Sarcoma GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04785820 | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 18 | Mar 27, 2026 | clinicaltrials |
| NCT04801147 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme(DENDR1) | completed | Phase 1 / Phase 2 | 76 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05226117 | Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer | completed | Phase 2 | 44 | IRCCS San RaffaeleOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02360579 | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma(LN-144) | completed | Phase 2 | 220 | Iovance Biotherapeutics, Inc.INDUSTRY | 8 | Mar 25, 2026 | clinicaltrials |
| NCT04383119 | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma(ISG-ARTICLE) | recruiting | Phase 2 | 100 | Italian Sarcoma GroupNETWORK | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03288545 | A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer(EV-103) | terminated | Phase 1 / Phase 2 | 348 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Mar 24, 2026 | clinicaltrials |
| NCT03410615 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | active not recruiting | Phase 2 | 129 | Canadian Cancer Trials GroupNETWORK | 4 | Mar 24, 2026 | clinicaltrials |
| NCT03915951 | An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | completed | Phase 2 | 98 | PfizerINDUSTRY | 5 | Mar 24, 2026 | clinicaltrials |
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 301 | Eisai Inc.INDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT04484142 | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | completed | Phase 2 | 137 | Daiichi SankyoINDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | recruiting | Phase 1 / Phase 2 | 606 | Sumitomo Pharma America, Inc.INDUSTRY | 12 | Mar 24, 2026 | clinicaltrials |
| NCT04639219 | A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations(DPT01) | active not recruiting | Phase 2 | 102 | AstraZenecaINDUSTRY | 9 | Mar 23, 2026 | clinicaltrials |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | active not recruiting | Phase 1 / Phase 2 | 253 | Taiho Oncology, Inc.INDUSTRY | 8 | Mar 20, 2026 | clinicaltrials |
| NCT02773030 | A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 466 | CelgeneINDUSTRY | 11 | Mar 20, 2026 | clinicaltrials |
| NCT07485296 | Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)(POST-BIO) | recruiting | Phase 2 | 45 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT01011920 | Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | completed | Phase 2 | 227 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 5 | Mar 19, 2026 | clinicaltrials |
| NCT04278768 | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | suspended | Phase 1 / Phase 2 | 366 | Curis, Inc.INDUSTRY | 8 | Mar 19, 2026 | clinicaltrials |
| NCT05733572 | Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)(NGF-OPG) | active not recruiting | Phase 2 | 36 | Benedetto FalsiniOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT03922100 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | terminated | Phase 1 / Phase 2 | 63 | Nerviano Medical SciencesINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-01) | active not recruiting | Phase 1 / Phase 2 | 344 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT02467270 | Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses(OPTIC) | completed | Phase 2 | 283 | TakedaINDUSTRY | 21 | Mar 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials